April 17, 2024
Repeating himself for the second time in the last several weeks, a federal judge in Delaware on Wednesday said he won't stop a biochemical startup from launching a drug that would compete directly with one of United Therapeutics' biggest pharmaceutical products.
March 29, 2024
A Delaware federal judge has ruled that biochemical startup Liquidia can launch its lung disease drug after the Federal Circuit upheld a patent board ruling cutting out the remaining claims in a hypertension patent owned by United Therapeutics that was keeping the drug off the market.
March 12, 2024
The full Federal Circuit on Tuesday declined to review a panel ruling from late last year that sided with a Patent Trial and Appeal Board decision that there was nothing patentable about a way of administering a blockbuster pulmonary hypertension drug.
December 20, 2023
The Federal Circuit decided Wednesday to leave untouched a ruling from the patent board that found there was nothing patentable about a purportedly new way of administering a blockbuster pulmonary hypertension drug, potentially shaking up drugmaker United Therapeutics' legal victory against a generic in Delaware federal court.
September 01, 2022
A Delaware federal judge has invalidated one of United Therapeutics' drug patents for hypertension drug Tyvaso for lack of enablement, but also held that rival Liquidia's planned generic infringes a different Tyvaso patent despite an administrative tribunal's earlier decision to ax it.